Patent ID: 8124088
Filing Date: 2012-02-28
Classification: A61K,A61P,C07K,Y10S

Abstract:
1. A method of treating a human afflicted with an IL-22RA-mediated inflammatory disease, the method comprising: administering to the human an effective amount of a neutralizing anti-IL-22RA antibody or antigen-binding fragment thereof, that binds to the same epitope on the polypeptide of SEQ ID NO:2 or SEQ ID NO:3 as a monoclonal antibody expressed by a hybridoma selected from the group consisting of: (a) the hybridoma clone 280.46.3.4 (ATCC Patent Deposit Designation PTA-6284), (b) the hybridoma clone 281.73.49.1.1 (ATCC Patent Deposit Designation PTA-6285), (c) the hybridoma clone 283.4.1.2 (ATCC Patent Deposit Designation PTA-6287), (d) the hybridoma clone 283.52.5.4 (ATCC Patent Deposit Designation PTA-6311), and (e) the hybridoma clone 283.108.2.3 (ATCC Patent Deposit Designation PTA 6286).